EICHOR
● Completed
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients
Condition: Primary Immunodeficiency Disease · Sponsor: Kedrion S.p.A.
About this study
The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (11)
| Allergy Associates of the Palm Beaches | North Palm Beach, Florida, United States | — |
| Rush University Medical Center | Chicago, Illinois, United States | — |
| Dr. Henry J. Kanarek - Allergy, Asthma & Immunology | Overland Park, Kansas, United States | — |
| Midwest Immunology Clinic and Infusion Center | Plymouth, Minnesota, United States | — |
| Allergy and Immunology Associates | Little Silver, New Jersey, United States | — |
| University of Buffalo | Buffalo, New York, United States | — |
| Optimed Research | Columbus, Ohio, United States | — |
| Ohio Clinical Research Associates, Inc. | Mayfield Heights, Ohio, United States | — |
| Toledo Institute of Clinical Research Inc | Toledo, Ohio, United States | — |
| Allergy Partners of North Texas Research | Dallas, Texas, United States | — |
| AARA Research Center | Dallas, Texas, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03961009